ClinicalTrials.gg
TerminatedNCT03138499CheckMate 812Updated Jan 10, 2024Results posted

A Study of Nivolumab Plus Brentuximab Vedotin Versus Brentuximab Vedotin Alone in Patients With Advanced Stage Classical Hodgkin Lymphoma, Who Are Relapsed/ Refractory or Who Are Not Eligible for Autologous Stem Cell Transplant,

A Phase 3 interventional study of Nivolumab and Brentuximab vedotin in Hodgkin's Disease, sponsored by Bristol-Myers Squibb. Terminated at 22 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-01-10.

Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment

Why this study was terminated
Insufficient enrollment.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
23
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 52 studies testing nivolumab in Hodgkin Disease — 17 open to participants now, 32 under way, 4 of them phase 3. Nivolumab · Hodgkin Disease.

Enrollment
42nd of 52
23 · median 52
Started
2017
with 8 others
Phase 3
3 of 52
1 open now
Registered
15th of 52
by date
Lead sponsor
5 of 52
Bristol-Myers Squibb

Among the 52 studies testing nivolumab in Hodgkin Disease, this one is the 42nd largest by enrollment, is one of 9 that started in 2017, is one of 3 in phase 3, and was the 15th registered.

Hodgkin Disease

1,383 studies on the registry are indexed under Hodgkin Disease; 163 are open to participants now.

Browse Hodgkin Disease studies →

Open to participants now

17 of the 52 studies testing nivolumab in Hodgkin Disease are open now, in 11 countries. Recruiting first, the newest first:

12 more — sign in →

By country, each count listing its studies:

All 17 open studies →

About nivolumab

Nivolumab: first FDA approval 2014 (OPDIVO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 136 Hodgkin Disease studies recruiting now, 73 (54%) set no upper age limit and 51 (38%) stop at 75 or younger; 46 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 52 studies testing nivolumab in Hodgkin Disease, or all of them as a file.
02

Study summary

The purpose of this study is to determine whether an investigational immuno-therapy combination, nivolumab with Brentuximab vedotin compared to Brentuximab vedotin alone is safe and effective in the treatment of relapsed and refractory Classical Hodgkin Lymphoma. The participants of this trial will comprise of patients who have relapsed or did not respond to treatment and are not eligible for stem cell transplant

03

Conditions studied

  • Hodgkin's Disease

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (ECOG) performance status (PS) 0 or 1.
  • Participants must have a pathologic diagnosis of classical Hodgkin lymphoma (cHL) who are with one of the following:.

    i) stem cell transplant (ASCT) ineligible patients.

ii) Patients after failure of ASCT.

  • Must have at least one lesion that is > 15 mm (1.5 cm) in the longest diameter and avid by Fluoro Deoxy Glucose (FDG) Positron Emission Tomography (PET) scan.

Exclusion criteria

Exclusion Criteria

  • Known central nervous system lymphoma.
  • Participants with nodular lymphocyte-predominant Hodgkin lymphoma (HL).
  • Participants with known history of pancreatitis or progressive multifocal leukoencephalopathy (PML).
  • Other protocol-defined Inclusion/Exclusion criteria apply.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
23 participants (actual)

Study arms

  • Experimental
    Module A

    Nivolumab combined with Brentuximab

    Biological: Nivolumab · Biological: Brentuximab vedotin

  • Experimental
    Module B

    Brentuximab alone

    Biological: Brentuximab vedotin

Interventions

  • BiologicalNivolumab

    Specified dose on specified days

    Also known as: Opdivo

  • Specified dose on specified days

    Also known as: Adcetris

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS)

    Progression Free Survival (PFS) is defined as time from date of randomization to death, or disease progression per investigator assessment estimated using the Kaplan-Meier (KM) product-limit method.

    Time frame: From randomization to date of death, or disease progression (up to approximately 45 months)

Secondary outcomes

  1. Complete Response Rate (CRR):

    Complete Response Rate (CRR) is defined as the number of participants who have achieved complete response (Lugano 2014 classification) per investigator assessment. Complete response is considered a score of 1, 2, or 3. Per the Lugano criteria: Positron emission tomography (PET) negative scans are defined on the 5-point scale as scores of 1, 2, or 3 (where 1 = no uptake above background; 2 = uptake \</= mediastinum; and 3 = uptake \> mediastinum but \</= liver) and PET-positive scans, as scores of 4 or 5 (where 4 = uptake moderately higher than liver; 5 = uptake markedly higher than liver and/or new lesions). Response on PET scans should be reported as complete metabolic response (CMR) partial metabolic response (PMR), SMD (stable metabolic disease), or PMD (progressive metabolic disease).

    Time frame: From randomization up to approximately 45 months

  2. Objective Response Rate (ORR)

    Objective Response Rate (ORR) is defined as the number of participants with a Best Overall Response (BOR) of complete response (CR) or partial response (PR) (Lugano 2014 classification) per investigator assessment. Complete response is considered a score of 1, 2, or 3. Partial response is considered a score of 4 or 5. Per the Lugano criteria: Positron emission tomography (PET) negative scans are defined on the 5-point scale as scores of 1, 2, or 3 (where 1 = no uptake above background; 2 = uptake \</= mediastinum; and 3 = uptake \> mediastinum but \</= liver) and PET-positive scans, as scores of 4 or 5 (where 4 = uptake moderately higher than liver; 5 = uptake markedly higher than liver and/or new lesions). Response on PET scans should be reported as complete metabolic response (CMR) partial metabolic response (PMR), SMD (stable metabolic disease), or PMD (progressive metabolic disease).

    Time frame: From randomization up to approximately 45 months

  3. Duration of Response (DOR)

    The time from first response (Complete response (CR) or partial response (PR)) to the date of initial objectively documented progression (2014 Lugano classification) or death due to any cause per investigator assessment estimated using the Kaplan-Meier (KM) product-limit method. Complete response is considered a score of 1, 2, or 3. Partial response is considered a score of 4 or 5. Per the Lugano criteria: Positron emission tomography (PET) negative scans are defined on the 5-point scale as scores of 1, 2, or 3 (where 1 = no uptake above background; 2 = uptake \</= mediastinum; and 3 = uptake \> mediastinum but \</= liver) and PET-positive scans, as scores of 4 or 5 (where 4 = uptake moderately higher than liver; 5 = uptake markedly higher than liver and/or new lesions). Response on PET scans should be reported as complete metabolic response (CMR) partial metabolic response (PMR), SMD (stable metabolic disease), or PMD (progressive metabolic disease).

    Time frame: From randomization to date of documented progression or death (up to approximately 45 months)

  4. Duration of Complete Response (DOCR)

    Duration of complete response (DOR) is defined as the time from first complete response to the date of initial objectively documented progression (2014 Lugano classification) or death due to any cause per investigator assessment estimated using the Kaplan-Meier (KM) product-limit method. Complete response is considered a score of 1, 2, or 3. Per the Lugano criteria: Positron emission tomography (PET) negative scans are defined on the 5-point scale as scores of 1, 2, or 3 (where 1 = no uptake above background; 2 = uptake \</= mediastinum; and 3 = uptake \> mediastinum but \</= liver) and PET-positive scans, as scores of 4 or 5 (where 4 = uptake moderately higher than liver; 5 = uptake markedly higher than liver and/or new lesions). Response on PET scans should be reported as complete metabolic response (CMR) partial metabolic response (PMR), SMD (stable metabolic disease), or PMD (progressive metabolic disease).

    Time frame: From randomization to date of documented progression or death (up to approximately 45 months)

  5. Overall Survival (OS)

    Overall Survival (OS) is defined as the time between the date of randomization and the date of death estimated using the Kaplan-Meier (KM) product-limit method

    Time frame: From randomization to the date of death (up to approximately 3 years 7 months)

07

Results

Posted Apr 12, 2022
Limitations and caveats
Due to a treatment paradigm shift and subsequent low enrollment, the Sponsor chose to terminate the study and consequently there is limited data. These reasons were unrelated to any adverse events (AEs) or safety concerns. The sample size was smaller than expected, therefore, results should be interpreted with caution. PFS, CRR, and ORR outcomes should be interpreted with caution given large confidence intervals around medians and early study closure.

Participant flow

Participant flow — Overall Study
MilestoneNivolumab + Brentuximab Vedotin (BV)Brentuximab Vedotin (BV)
Started1211
Completed31
Not completed910
Withdrew: Lost to follow-up10
Withdrew: Participants withdrew consent10
Withdrew: Participant discontinued study before treatment01
Withdrew: Disease progression26
Withdrew: Study drug toxicity22
Withdrew: Participant request to discontinue study treatment11
Withdrew: Other reasons20

Outcome measures

PrimaryProgression Free Survival (PFS)

Progression Free Survival (PFS) is defined as time from date of randomization to death, or disease progression per investigator assessment estimated using the Kaplan-Meier (KM) product-limit method.

Time frame:
From randomization to date of death, or disease progression (up to approximately 45 months)
Reported as:
Median · Months
Progression Free Survival (PFS)
MonthsNivolumab + Brentuximab Vedotin (BV)Brentuximab Vedotin (BV)
Progression Free Survival (PFS)14.32 (10.12 to NA)7.93 (2.86 to NA)
SecondaryComplete Response Rate (CRR):

Complete Response Rate (CRR) is defined as the number of participants who have achieved complete response (Lugano 2014 classification) per investigator assessment. Complete response is considered a score of 1, 2, or 3. Per the Lugano criteria: Positron emission tomography (PET) negative scans are defined on the 5-point scale as scores of 1, 2, or 3 (where 1 = no uptake above background; 2 = uptake \</= mediastinum; and 3 = uptake \> mediastinum but \</= liver) and PET-positive scans, as scores of 4 or 5 (where 4 = uptake moderately higher than liver; 5 = uptake markedly higher than liver and/or new lesions). Response on PET scans should be reported as complete metabolic response (CMR) partial metabolic response (PMR), SMD (stable metabolic disease), or PMD (progressive metabolic disease).

Time frame:
From randomization up to approximately 45 months
Reported as:
Count of participants · Participants
Complete Response Rate (CRR):
ParticipantsNivolumab + Brentuximab Vedotin (BV)Brentuximab Vedotin (BV)
Complete Response Rate (CRR):43
SecondaryObjective Response Rate (ORR)

Objective Response Rate (ORR) is defined as the number of participants with a Best Overall Response (BOR) of complete response (CR) or partial response (PR) (Lugano 2014 classification) per investigator assessment. Complete response is considered a score of 1, 2, or 3. Partial response is considered a score of 4 or 5. Per the Lugano criteria: Positron emission tomography (PET) negative scans are defined on the 5-point scale as scores of 1, 2, or 3 (where 1 = no uptake above background; 2 = uptake \</= mediastinum; and 3 = uptake \> mediastinum but \</= liver) and PET-positive scans, as scores of 4 or 5 (where 4 = uptake moderately higher than liver; 5 = uptake markedly higher than liver and/or new lesions). Response on PET scans should be reported as complete metabolic response (CMR) partial metabolic response (PMR), SMD (stable metabolic disease), or PMD (progressive metabolic disease).

Time frame:
From randomization up to approximately 45 months
Reported as:
Count of participants · Participants
Objective Response Rate (ORR)
ParticipantsNivolumab + Brentuximab Vedotin (BV)Brentuximab Vedotin (BV)
Objective Response Rate (ORR)85
SecondaryDuration of Response (DOR)

The time from first response (Complete response (CR) or partial response (PR)) to the date of initial objectively documented progression (2014 Lugano classification) or death due to any cause per investigator assessment estimated using the Kaplan-Meier (KM) product-limit method. Complete response is considered a score of 1, 2, or 3. Partial response is considered a score of 4 or 5. Per the Lugano criteria: Positron emission tomography (PET) negative scans are defined on the 5-point scale as scores of 1, 2, or 3 (where 1 = no uptake above background; 2 = uptake \</= mediastinum; and 3 = uptake \> mediastinum but \</= liver) and PET-positive scans, as scores of 4 or 5 (where 4 = uptake moderately higher than liver; 5 = uptake markedly higher than liver and/or new lesions). Response on PET scans should be reported as complete metabolic response (CMR) partial metabolic response (PMR), SMD (stable metabolic disease), or PMD (progressive metabolic disease).

Time frame:
From randomization to date of documented progression or death (up to approximately 45 months)
Reported as:
Median · Months
Duration of Response (DOR)
MonthsNivolumab + Brentuximab Vedotin (BV)Brentuximab Vedotin (BV)
Duration of Response (DOR)11.27 (7.39 to 11.27)7.00 (1.54 to NA)
SecondaryDuration of Complete Response (DOCR)

Duration of complete response (DOR) is defined as the time from first complete response to the date of initial objectively documented progression (2014 Lugano classification) or death due to any cause per investigator assessment estimated using the Kaplan-Meier (KM) product-limit method. Complete response is considered a score of 1, 2, or 3. Per the Lugano criteria: Positron emission tomography (PET) negative scans are defined on the 5-point scale as scores of 1, 2, or 3 (where 1 = no uptake above background; 2 = uptake \</= mediastinum; and 3 = uptake \> mediastinum but \</= liver) and PET-positive scans, as scores of 4 or 5 (where 4 = uptake moderately higher than liver; 5 = uptake markedly higher than liver and/or new lesions). Response on PET scans should be reported as complete metabolic response (CMR) partial metabolic response (PMR), SMD (stable metabolic disease), or PMD (progressive metabolic disease).

Time frame:
From randomization to date of documented progression or death (up to approximately 45 months)
Reported as:
Median · Months
Duration of Complete Response (DOCR)
MonthsNivolumab + Brentuximab Vedotin (BV)Brentuximab Vedotin (BV)
Duration of Complete Response (DOCR)7.85 (NA to NA)NA (NA to NA)
SecondaryOverall Survival (OS)

Overall Survival (OS) is defined as the time between the date of randomization and the date of death estimated using the Kaplan-Meier (KM) product-limit method

Time frame:
From randomization to the date of death (up to approximately 3 years 7 months)
Reported as:
Median · Months
Overall Survival (OS)
MonthsNivolumab + Brentuximab Vedotin (BV)Brentuximab Vedotin (BV)
Overall Survival (OS)NA (25.40 to NA)NA (NA to NA)

Adverse events

Collected over From first dose to up to 100 days post last dose (up to approximately 2 years) All-cause mortality was assessed from date of first dose to study completion (up to approximately 3 years 7 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Nivolumab + Brentuximab Vedotin (BV)1/12 (8.3%)6/12 (50%)12/12 (100%)
Brentuximab Vedotin (BV)0/10 (0%)1/10 (10%)10/10 (100%)
Most frequent serious events
Most frequent serious events
EventNivolumab + Brentuximab Vedotin (BV)Brentuximab Vedotin (BV)
Infusion related reactionInjury, poisoning and procedural complications2/120/10
Non-cardiac chest painGeneral disorders0/121/10
EmbolismVascular disorders0/121/10
PyrexiaGeneral disorders1/120/10
Adenovirus infectionInfections and infestations1/120/10
Herpes zosterInfections and infestations1/120/10
SeizureNervous system disorders1/120/10
EpistaxisRespiratory, thoracic and mediastinal disorders1/120/10
Pulmonary embolismRespiratory, thoracic and mediastinal disorders1/120/10
RashSkin and subcutaneous tissue disorders1/120/10
Most frequent other events
Showing 10 of 117
Most frequent other events
EventNivolumab + Brentuximab Vedotin (BV)Brentuximab Vedotin (BV)
Neuropathy peripheralNervous system disorders6/126/10
FatigueGeneral disorders6/124/10
HeadacheNervous system disorders6/122/10
ConstipationGastrointestinal disorders5/121/10
CoughRespiratory, thoracic and mediastinal disorders5/122/10
NauseaGastrointestinal disorders4/124/10
PruritusSkin and subcutaneous tissue disorders1/124/10
Non-cardiac chest painGeneral disorders4/120/10
PyrexiaGeneral disorders4/122/10
Peripheral sensory neuropathyNervous system disorders4/121/10

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Nivolumab + Brentuximab Vedotin (BV)Brentuximab Vedotin (BV)Total
Mean37.5 ± 13.142.3 ± 16.139.8 ± 14.5
Sex: Female, Male
Sex: Female, Male(Participants)Nivolumab + Brentuximab Vedotin (BV)Brentuximab Vedotin (BV)Total
Female538
Male7815
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Nivolumab + Brentuximab Vedotin (BV)Brentuximab Vedotin (BV)Total
Hispanic or Latino235
Not Hispanic or Latino9716
Unknown or Not Reported112
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Nivolumab + Brentuximab Vedotin (BV)Brentuximab Vedotin (BV)Total
WHITE7411
BLACK OR AFRICAN AMERICAN325
JAPANESE011
ASIAN OTHER011
NATIVE HAWAIIAN OR OTHER PACIFIC ISLANDER101
OTHER134
08

Study locations

22 sites
  • City of Hope National Medical Center
    Duarte, California 91010, United States
  • Pacific Shores Medical Group
    Long Beach, California 90813, United States
  • University of Southern California
    Los Angeles, California 90033, United States
  • UCLA Clinical and Translational Research Center (CTRC)
    Los Angeles, California 90095-1678, United States
  • Local Institution
    Palo Alto, California 94304, United States
  • UC Davis Comprehensive Cancer Center
    Sacramento, California 95817, United States
  • University of California San Diego
    San Diego, California 92122, United States
  • Hartford Healthcare Cancer Institute at the Hospital of Central Connecticut
    Plainville, Connecticut 06062, United States
  • Orlando Health, Inc
    Orlando, Florida 32806, United States
  • Parkview Cancer Center
    Fort Wayne, Indiana 46845, United States
  • University of Kansas Cancer Center
    Westwood, Kansas 66205, United States
  • Tulane University Health Sciences Center
    New Orleans, Louisiana 70112, United States
  • Dana Farber/Harvard Cancer Center
    Boston, Massachusetts 02215, United States
  • Karmanos Cancer Institute
    Detroit, Michigan 48201, United States
  • Wake Forest University Health Sciences
    Winston-Salem, North Carolina 27157, United States
  • University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • Bon Secours Saint Francis Cancer Center
    Greenville, South Carolina 29607, United States
  • Vanderbilt Ingram Cancer Center
    Nashville, Tennessee 37213, United States
  • University of Texas Southwestern Medical Center
    Dallas, Texas 75390, United States
  • The University of Texas MD Anderson Cancer Center-merge
    Houston, Texas 77030, United States
  • Local Institution
    Sendai-shi, Miyagi 9808574, Japan
  • Local Institution
    San Juan, 00918, Puerto Rico
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2017 to primary completion in Feb 2021, 43 months.

Results were first posted in Apr 2022, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 1, 2017
First posted
May 3, 2017
StartActual
Jun 26, 2017
Primary completionActual
Feb 22, 2021
CompletionActual
Feb 22, 2021
Results first posted
Apr 12, 2022
Last update
Jan 10, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 10, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03138499
Responsible party
Sponsor
First posted
May 3, 2017
Start date
Jun 26, 2017
Primary completion
Feb 22, 2021
Completion
Feb 22, 2021
Results posted
Apr 12, 2022
Last update
Jan 10, 2024

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Nivolumab · Brentuximab Vedotin

Start the discussion